– USA, MA –  Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, today announced that Christopher Noel Dunn, Jordan Heller, and Diane K. Jorkasky, MD, FACP, have been appointed to its board of directors.

About Noel Dunn

Noel Dunn serves as Executive Chairman and director of Ero Copper Corporation. Mr. Dunn has 25 years of experience in investment banking, primarily with Goldman Sachs managing the capital underwriting business in London. Previously, at Bear Stearns and JP Morgan, he led their respective investment banking practices in mining and metals. Mr. Dunn holds a Master of Arts degree from the University of Edinburgh and a Master of Science degree from the University of Durham.

“Noel brings an outstanding track record of financial transactions, investment and company-building experience to Alzheon’s Board,” said Neil Flanzraich, JD, Executive Chairman of Alzheon’s board of directors. “His keen insights will help sharpen our business and investment strategies.”

About Jordan Heller

Jordan Heller is Managing Director and Partner of Beacon Pointe Wealth Advisors. Prior to entering the wealth management industry, Mr. Heller spent 15 years on Wall Street heading real estate finance securities at Merrill Lynch, Salomon Brothers and CIBC. During this time, Mr. Heller played a leading role in the rebirth of the modern real estate investment trust industry.

“Jordan brings a diversity of experience in value-generation from an investor perspective and deep insights into institutional investment. We look forward to his expertise as we build and finance Alzheon’s business,” commented Mr. Flanzraich.

About Dr. Diane Jorkasky

Dr. Diane Jorkasky most recently served as Chief Medical Officer, Head of Development and EVP at Complexa, Inc., a company developing new medicines for rare diseases. Previously, at Pfizer Global R&D, she served as Vice President of Global Clinical Research Operations, responsible for exploratory development, clinical pharmacology, and translational medicine.

“I am honored to serve on Alzheon’s board as the company emerges as a frontrunner in the race to develop a safe, oral disease-modifying treatment for patients and families affected by Alzheimer’s,” said Dr. Jorkasky. “Alzheon has advanced the understanding of the critical role that toxic amyloid oligomers play in Alzheimer’s pathophysiology, and I look forward to seeing the company’s promising therapy, ALZ-801, in a confirmatory Phase 3 trial.”

Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology, and received her medical degree from the University of Pennsylvania.

“We are excited to have Diane, an accomplished physician-scientist, bring her wealth of clinical development experience as we advance ALZ-801 to Phase 3, as a groundbreaking oral treatment for Alzheimer’s disease,” said Mr. Flanzraich.

About Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of beta-amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact on patients.

For more information: https://alzheon.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.